ABS-103(Amberstone Biosciences)

N/A

Report date: 2026/03/19 17:12:19

Base Information

Drug NameABS-103(Amberstone Biosciences)

Drug Alias NameABS-103(Amberstone Biosciences)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD3 T-cell engagersTumor-associated antigen modulators

TargetsT cell surface glycoprotein CD3Tumor-associated antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmberstone Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmberstone Biosciences Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A